DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/2qbc6p/myelodysplastic) has announced the addition of the "Myelodysplastic Syndrome - Pipeline Review, H1 2015" report to their offering.
This report provides comprehensive information on the therapeutic development for Myelodysplastic Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myelodysplastic Syndrome and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies Involved in Therapeutics Development (Partial List)
- 4SC AG
- AbbVie Inc.
- Acceleron Pharma, Inc.
- Actinium Pharmaceuticals, Inc.
- Advancell
- Agios Pharmaceuticals, Inc.
- Altor BioScience Corporation
- Amgen Inc.
- Apogenix GmbH
- Aptose Biosciences Inc.
- Array BioPharma Inc.
- Astex Pharmaceuticals, Inc.
- Bio-Path Holdings, Inc.
- BioLineRx, Ltd.
- Boehringer Ingelheim GmbH
- Boryung Pharmaceutical Co., Ltd.
- Boston Biomedical, Inc.
- Bristol-Myers Squibb Company
- Celator Pharmaceuticals, Inc.
- Celgene Corporation
- Celldex Therapeutics, Inc.
- Cellerant Therapeutics, Inc.
- Celyad
- Clevexel Pharma SAS
- Concert Pharmaceuticals, Inc.
- Constellation Pharmaceuticals, Inc.
- Cornerstone Pharmaceuticals, Inc.
- CTI BioPharma Corp.
- Cyclacel Pharmaceuticals, Inc.
- Daiichi Sankyo Company, Limited
- Eisai Co., Ltd.
- Eleos Inc.
- Eli Lilly and Company
- EpiZyme, Inc.
-
F. Hoffmann-La Roche Ltd
For more information visit http://www.researchandmarkets.com/research/2qbc6p/myelodysplastic
